These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
282 related articles for article (PubMed ID: 36272280)
1. IL-9 stimulates an anti-tumor immune response and facilitates immune checkpoint blockade in the CMT167 mouse model. Feng Y; Yan S; Lam SK; Ko FCF; Chen C; Khan M; Ho JC Lung Cancer; 2022 Dec; 174():14-26. PubMed ID: 36272280 [TBL] [Abstract][Full Text] [Related]
2. The Tumor Microenvironment Regulates Sensitivity of Murine Lung Tumors to PD-1/PD-L1 Antibody Blockade. Li HY; McSharry M; Bullock B; Nguyen TT; Kwak J; Poczobutt JM; Sippel TR; Heasley LE; Weiser-Evans MC; Clambey ET; Nemenoff RA Cancer Immunol Res; 2017 Sep; 5(9):767-777. PubMed ID: 28819064 [TBL] [Abstract][Full Text] [Related]
3. Blocking LTB Yan J; Zhu J; Li X; Yang R; Xiao W; Huang C; Zheng C Phytomedicine; 2023 Oct; 119():154968. PubMed ID: 37531900 [TBL] [Abstract][Full Text] [Related]
4. Gemcitabine and checkpoint blockade exhibit synergistic anti-tumor effects in a model of murine lung carcinoma. Du B; Wen X; Wang Y; Lin M; Lai J Int Immunopharmacol; 2020 Sep; 86():106694. PubMed ID: 32570034 [TBL] [Abstract][Full Text] [Related]
5. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner. Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370 [TBL] [Abstract][Full Text] [Related]
7. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation. Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094 [No Abstract] [Full Text] [Related]
8. Cancer Cell-Intrinsic Expression of MHC Class II Regulates the Immune Microenvironment and Response to Anti-PD-1 Therapy in Lung Adenocarcinoma. Johnson AM; Bullock BL; Neuwelt AJ; Poczobutt JM; Kaspar RE; Li HY; Kwak JW; Hopp K; Weiser-Evans MCM; Heasley LE; Schenk EL; Clambey ET; Nemenoff RA J Immunol; 2020 Apr; 204(8):2295-2307. PubMed ID: 32179637 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of COX-2 and EGFR by Melafolone Improves Anti-PD-1 Therapy through Vascular Normalization and PD-L1 Downregulation in Lung Cancer. Tang H; Liu Y; Wang C; Zheng H; Chen Y; Liu W; Chen X; Zhang J; Chen H; Yang Y; Yang J J Pharmacol Exp Ther; 2019 Mar; 368(3):401-413. PubMed ID: 30591531 [TBL] [Abstract][Full Text] [Related]
10. Combination of PD-1 Checkpoint Blockade and Botulinum Toxin Type A1 Improves Antitumor Responses in Mouse Tumor Models of Melanoma and Colon Carcinoma. Kwak S; Lee JY; Kim MJ; Lee HJ; Lee DK; Kang J; Kang WH; Son WC; Cruz DJM Immunol Invest; 2023 Nov; 52(6):749-766. PubMed ID: 37403798 [TBL] [Abstract][Full Text] [Related]
11. Synergic effect of PD-1 blockade and endostar on the PI3K/AKT/mTOR-mediated autophagy and angiogenesis in Lewis lung carcinoma mouse model. Wu J; Zhao X; Sun Q; Jiang Y; Zhang W; Luo J; Li Y Biomed Pharmacother; 2020 May; 125():109746. PubMed ID: 32106386 [TBL] [Abstract][Full Text] [Related]
13. HOXC9 characterizes a suppressive tumor immune microenvironment and integration with multiple immune biomarkers predicts response to PD-1 blockade plus chemotherapy in lung adenocarcinoma. Liu L; Zhang Z; Jiang C; Zhu Y; Han R; Wu L; Xu Y Aging (Albany NY); 2024 Mar; 16(5):4841-4861. PubMed ID: 38446596 [TBL] [Abstract][Full Text] [Related]
14. Targeted overexpression of prostacyclin synthase inhibits lung tumor progression by recruiting CD4+ T lymphocytes in tumors that express MHC class II. Li HY; McSharry M; Walker D; Johnson A; Kwak J; Bullock B; Neuwelt A; Poczobutt JM; Sippel TR; Keith RL; Weiser-Evans MCM; Clambey E; Nemenoff RA Oncoimmunology; 2018; 7(5):e1423182. PubMed ID: 29721380 [TBL] [Abstract][Full Text] [Related]
15. METTL14 regulates CD8 Sun C; Wang J; Li H; Liu L; Lin Y; Zhang L; Zu X; Zhu Y; Shu Y; Shen D; Wang Q; Liu Y World J Surg Oncol; 2024 May; 22(1):128. PubMed ID: 38725005 [TBL] [Abstract][Full Text] [Related]
16. Combined application of bevacizumab and PD-1 blockade displays durable treatment effects by increasing the infiltration and cytotoxic function of CD8 Liu Y; Zhang T; Zhang L; Zhao C; Zhang Z; Wang Z; Gu M; Li W; Li B Immunotherapy; 2022 Jun; 14(9):695-708. PubMed ID: 35574588 [TBL] [Abstract][Full Text] [Related]
17. A novel retinoic acid receptor-γ agonist antagonizes immune checkpoint resistance in lung cancers by altering the tumor immune microenvironment. Wei CH; Huang L; Kreh B; Liu X; Tyutyunyk-Massey L; Kawakami M; Chen Z; Shi M; Kozlov S; Chan KC; Andresson T; Carrington M; Vuligonda V; Sanders ME; Horowitz A; Hwu P; Peng W; Dmitrovsky E; Liu X Sci Rep; 2023 Sep; 13(1):14907. PubMed ID: 37689790 [TBL] [Abstract][Full Text] [Related]
18. Near-infrared duocarmycin photorelease from a Treg-targeted antibody-drug conjugate improves efficacy of PD-1 blockade in syngeneic murine tumor models. Fukushima H; Furusawa A; Takao S; Thankarajan E; Luciano MP; Usama SM; Kano M; Okuyama S; Yamamoto H; Suzuki M; Kano M; Choyke PL; Schnermann MJ; Kobayashi H Oncoimmunology; 2024; 13(1):2370544. PubMed ID: 38915782 [TBL] [Abstract][Full Text] [Related]
19. Single-cell RNA sequencing reveals the effects of anti-PD-L1 therapy on 3LL lung cancer model and its tumor microenvironment. Zhang H; Huang H; Wu S; He X; Chen J; Zheng X; Chen L; Wang Z Med Oncol; 2023 Aug; 40(10):285. PubMed ID: 37653265 [TBL] [Abstract][Full Text] [Related]
20. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer. Liu C; Liu R; Wang B; Lian J; Yao Y; Sun H; Zhang C; Fang L; Guan X; Shi J; Han S; Zhan F; Luo S; Yao Y; Zheng T; Zhang Y J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462141 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]